Gamma irradiated HPL enables safe and efficient cell expansion

Transferring cell therapies to the clinic requires large-scale and cost-effective manufacturing platforms for functional cells to be effectively produced at the scale required to meet clinical demand. For mesenchymal stem cells (MSC) and T cell therapies in particular, using human platelet lysate (HPL) in cultures has been found to be key in the safe and efficient expansion of cells ex vivo.  

This research spotlight summarizes a recent poster presented by Mill Creek Life Sciences demonstrating human platelet lysates that have been treated with gamma irradiation for pathogen reduction and the expansion of T cells in 2D and 3D systems. Results show improved safety profile, cell yield, and cellular phenotype in comparison to other products available in the market.  

The Spotlight

Keywords: Cell therapy, T cell isolation, T cell culture, T cell expansion, MSC culture, MSC expansion, cell expansion, gene editing, CAR-T, CRISPR, clinical cell culture

Cell type(s): T cells, CAR-T cells, MSC, stem cells

Experiment purpose:

Expansion of MSCs and T cells using gamma irradiated human platelet lysate, shows unprecedented levels
of product quality and efficiency, which improves the overall safety profile for cell-based products. 

Product highlights:

PLTMax® Human Platelet Lysate, Gamma Irradiated
Originally launched in 2010 and licensed through the Mayo Clinic, PLTMax was the first commercially available human platelet lysate to hit the market. PLTMax requires heparin and is used in several clinical trials worldwide. 

PLTGold® Human Platelet Lysate, Gamma Irradiated
PLTGold is a next generation, growth factor rich, xeno-free, heparin-free supplement that is a superior alternative to FBS or human AB serum. 

References: Alonso-Camino et al. Development of a gamma irradiated human platelet lysate for high efficiency cGMP expansion of therapeutic stem cells. 2021. Mill Creek Life Sciences. Poster. 

Alonso-Camino et al. Expansion of different types of therapeutic cells using xenogenic free and gamma irradiated human platelet lysate. 2022. Mill Creek Life Sciences. Scientific. Poster.

Conclusion

With the continued development of cell-based therapies, PLTMax and PLTGold human platelet lysate meet the need for a cGMP, clinical grade culture supplement that is consistent, reliable, and cost-effective for large culture scale-up applications.  PLTMax-GI and PLTGold-GI hPL have been treated with gamma irradiation for pathogen reduction in a process that maintains unprecedented levels of reagent quality and efficiency.  PLTMax-GI and PLTGold-GI offer outstanding growth, with further pathogen reduction to improve the safety profile of cell products.  

Want to know more about PLTMax or PLTGold human platelet lysate?
Download our Research Spotlight to learn more about the highlights of this research poster.

Image source: Comparison data between PLTGold-GI and other commercially available gamma irradiated HPL solutions used as supplements for the expansion of T cells in vitro by Mill Creek Life Sciences.